Previous 10 | Next 10 |
Weyco Group Inc. (WEYS) is expected to report for Q1 2024 Gladstone Land Corporation (LAND) is expected to report $0.16 for Q3 2023 PlayAGS Inc. (AGS) is expected to report $0.01 for Q3 2023 Ardmore Shipping Corporation (ASC) is expected to report $0.43 for Q3 2023 Sage Therapeuti...
Genmab A/S (GMAB) is expected to report $0.34 for Q3 2023
2023-11-06 10:30:08 ET Major earnings expected before the bell on Tuesday include: Air Products and Chemicals ( APD ) Datadog ( DDOG ) D.R. Horton ( DHI ) Emerson Electric ( EMR ) Uber Technologies ( UBER ) For further details see: Notable...
Eighteen total abstracts accepted for presentation and publication, including results from four clinical trials evaluating epcoritamab in multiple treatment settings and patient populations Oral presentations highlighting new findings from a clinical trial of epcoritamab in patients with ...
2023-10-23 14:58:57 ET More on Genmab, Seagen, etc. Zai Lab Stock: De-Risking Through Market Tapping Seagen Acquisition By Pfizer: A Strategic Power Move With Potential Windfalls For Investors Genmab Is Down To Attractive Levels Seagen/ Astellas succeed in Ph...
TIVDAK demonstrated superior overall survival, progression-free survival and objective response rate compared to chemotherapy in late-breaking results presented at ESMO 2023 congress Results from innovaTV 301 intended to serve as pivotal confirmatory trial for U.S. accelerated approval an...
2023-10-18 12:46:20 ET More on Genmab Genmab Is Down To Attractive Levels Genmab A/S (GMAB) Q2 2023 Earnings Call Transcript Seagen, Genmab succeed in Phase 3 trial for cervical cancer therapy Genmab raises FY 2023 guidance on back of Darzalex sales S...
2023-10-18 08:27:42 ET Nuzee ( NUZE ) -33% on proposed public offering of shares . SciSparc ( SPRC ) -16% . Notable Labs (NTBL) -10% . Genmab ( GMAB ) -9% . Maison Solutions ( MSS ) -8% . Aldeyra Therapeutics ( ALDX ...
2023-10-17 07:11:38 ET More on Johnson & Johnson Johnson & Johnson: A Conservative High-Yield Dividend Aristocrat Buy Johnson & Johnson Q3 Earnings Preview: Don't Count On Different Proposition Post Kenvue Spin-Out Johnson & Johnson: The Bull Case Can...
Company Announcement Net sales of DARZALEX ® in the third quarter of 2023 totaled USD 2,499 million Genmab receives royalties on worldwide net sales from Janssen Biotech, Inc. (Janssen) COPENHAGEN, Denmark; October 17, 2023 – Genmab A/S ...
News, Short Squeeze, Breakout and More Instantly...
A look at the top 10 most actives in the United States Innovative Eyewear Inc. (LUCY) rose 78.0% to $0.58749 on volume of 130,454,575 shares Ocean Power Technologies Inc. (OPTT) rose 29.6% to $0.2073 on volume of 51,927,154 shares Cosmos Health Inc. (COSM) rose 64.9% to $1.12 on volume of...
Company Announcement Positive CHMP opinion based on results from the Phase 1/2 EPCORE ® NHL-1 study FL is the second most common type of NHL and accounts for approximately 20-30 percent of all global cases If approved, epcoritamab (TEPKINLY ® ...
2024-06-27 09:00:08 ET Kaveri Pohlman from BTIG issued a price target of $47.00 for GMAB on 2024-06-27 07:34:00. The adjusted price target was set to $47.00. At the time of the announcement, GMAB was trading at $25.67. The overall price target consensus is at $41.80 with...